|
ES2287971T3
(es)
|
1997-08-11 |
2007-12-16 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
|
|
ES2292238T3
(es)
*
|
1998-04-24 |
2008-03-01 |
Scarista Limited |
Tratamiento de la depresion y preparaciones farmaceuticas para el mismo.
|
|
US6960577B2
(en)
|
1998-05-22 |
2005-11-01 |
Eli Lilly And Company |
Combination therapy for treatment of refractory depression
|
|
HUP0101901A3
(en)
*
|
1998-05-22 |
2002-06-28 |
Lilly Co Eli |
Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
|
|
BR9911068A
(pt)
*
|
1998-05-29 |
2001-02-06 |
Lilly Co Eli |
Terapia combinada para tratamento de distúrbios bipolares
|
|
WO2000024399A1
(en)
*
|
1998-10-23 |
2000-05-04 |
Sepracor Inc. |
Compositions and methods employing r(-) fluoxetine and other active ingredients
|
|
EP1133299A1
(en)
*
|
1998-11-23 |
2001-09-19 |
Sepracor Inc. |
2-hydroxymethylolanzapine compositions and methods
|
|
ATE400251T1
(de)
*
|
1999-02-09 |
2008-07-15 |
Pfizer Prod Inc |
Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
|
|
US6706283B1
(en)
*
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
|
JP4854115B2
(ja)
|
1999-03-12 |
2012-01-18 |
エイシカ ファーマシューティカルス リミテッド |
無水パロキセチン用安定製剤形
|
|
JP2002544223A
(ja)
*
|
1999-05-12 |
2002-12-24 |
ソルベイ・フアーマシユーチカルズ・ベー・ブイ |
精神病性障害の治療方法
|
|
CA2363784A1
(en)
*
|
1999-05-19 |
2000-11-30 |
Astrazeneca Ab |
Method of treatment
|
|
WO2000074784A1
(en)
*
|
1999-06-09 |
2000-12-14 |
Eli Lilly And Company |
Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
|
|
AR021155A1
(es)
*
|
1999-07-08 |
2002-06-12 |
Lundbeck & Co As H |
Tratamiento de desordenes neuroticos
|
|
EP1220658A1
(en)
*
|
1999-09-28 |
2002-07-10 |
H. Lundbeck A/S |
Melt granulated composition and modified release dosage form prepared from said composition
|
|
AU3789901A
(en)
|
1999-12-17 |
2001-06-25 |
Bristol-Myers Squibb Company |
Antipsychotic heterocycle compounds
|
|
CN1402629A
(zh)
|
1999-12-23 |
2003-03-12 |
辉瑞产品公司 |
提供提高的药物浓度的药物组合物
|
|
US6572890B2
(en)
*
|
2000-01-13 |
2003-06-03 |
Osmotica Corp. |
Osmotic device containing venlafaxine and an anti-psychotic agent
|
|
JP2004502655A
(ja)
*
|
2000-06-30 |
2004-01-29 |
イーライ・リリー・アンド・カンパニー |
精神病の処置のための組み合わせ療法
|
|
US7666445B2
(en)
*
|
2000-10-20 |
2010-02-23 |
The Trustees Of The University Of Pennsylvania |
Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
|
|
US20030232881A1
(en)
*
|
2000-10-27 |
2003-12-18 |
H. Lundbeck A/S |
Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
|
|
CA2364211A1
(en)
*
|
2000-12-05 |
2002-06-05 |
Phillip Branch Chappell |
Combination treatment for depression, anxiety and psychosis
|
|
CA2431041A1
(en)
*
|
2001-01-02 |
2002-07-11 |
Pharmacia & Upjohn Company |
New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
|
|
US7304047B2
(en)
*
|
2001-02-06 |
2007-12-04 |
Astrazeneca Ab |
Method of treating substance abuse with quetiapine
|
|
US20020123490A1
(en)
*
|
2001-03-01 |
2002-09-05 |
Pfizer Inc. |
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
|
|
WO2002087566A1
(en)
*
|
2001-05-01 |
2002-11-07 |
H. Lundbeck A/S |
The use of enantiomeric pure escitalopram
|
|
US7034059B2
(en)
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
|
CA2529857A1
(en)
*
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
|
AR042806A1
(es)
|
2002-12-27 |
2005-07-06 |
Otsuka Pharma Co Ltd |
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
|
|
KR100842694B1
(ko)
|
2002-12-27 |
2008-07-01 |
오쓰까 세이야꾸 가부시키가이샤 |
기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
|
|
CA2525868A1
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Anxiety treatments with ziprasidone
|
|
EP1633360A1
(en)
*
|
2003-05-16 |
2006-03-15 |
Pfizer Products Incorporated |
Treatment of psychotic and depressive disorders
|
|
MXPA05012325A
(es)
*
|
2003-05-16 |
2006-01-30 |
Pfizer Prod Inc |
Procedimiento para potenciar la cognicion usando zipirasidona.
|
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
|
US20050032781A1
(en)
*
|
2003-08-06 |
2005-02-10 |
Elliot Ehrich |
Methods for administering active agents to CYP 2D6 sensitive patients
|
|
EP1708790B1
(en)
|
2003-12-02 |
2010-04-21 |
PharmaNeuroBoost N.V. |
Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
|
|
US7855195B2
(en)
|
2003-12-02 |
2010-12-21 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
EP1547650A1
(en)
*
|
2003-12-02 |
2005-06-29 |
B & B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
US7884096B2
(en)
|
2003-12-02 |
2011-02-08 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
EP1713486A4
(en)
*
|
2003-12-02 |
2009-04-29 |
Sheldon Leslie James |
COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
|
|
US20070155720A1
(en)
*
|
2003-12-23 |
2007-07-05 |
Darpharma, Inc. |
Co-administration of dopamine-receptor binding compounds
|
|
CA2553254C
(en)
*
|
2004-01-12 |
2013-12-17 |
The Trustees Of The University Of Pennsylvania |
Long-term delivery formulations and methods of use thereof
|
|
US8221778B2
(en)
|
2005-01-12 |
2012-07-17 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
|
US20050171088A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Astrazeneca Ab |
Treatment of psychoses with dibenzothiazepine antipsychotic
|
|
WO2006027800A1
(en)
*
|
2004-09-06 |
2006-03-16 |
Shasun Chemicals And Drugs Limited |
A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
|
|
WO2006083204A1
(en)
*
|
2004-12-27 |
2006-08-10 |
Alpha 2 Pharmaceutical Ab |
Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
|
|
CZ297214B6
(cs)
*
|
2005-02-02 |
2006-10-11 |
Zentiva, A. S. |
Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
|
|
UA97349C2
(uk)
*
|
2005-09-08 |
2012-02-10 |
Х. Луннбэк А/С |
Стійкі тверді склади сертиндолу
|
|
US20070093471A1
(en)
*
|
2005-10-26 |
2007-04-26 |
Alamo Pharmaceuticals, Llc |
Compositions and methods for the administration clozapine formulations which modulate body weight
|
|
PL2120878T3
(pl)
*
|
2007-02-09 |
2015-01-30 |
Alphapharm Pty Ltd |
Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
|
|
WO2008122019A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Cypress Biosciences, Inc. |
Improving the tolerability of both mirtazapine and reboxetine by using them in combination
|
|
US8198305B2
(en)
*
|
2007-04-13 |
2012-06-12 |
Concert Pharmaceuticals Inc. |
1,2-benzisoxazol-3-yl compounds
|
|
RU2508096C2
(ru)
*
|
2007-08-01 |
2014-02-27 |
Сергей Олегович Бачурин |
Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
|
|
RU2508106C2
(ru)
*
|
2007-08-01 |
2014-02-27 |
Сергей Олегович Бачурин |
Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
|
|
US20090036468A1
(en)
*
|
2007-08-03 |
2009-02-05 |
Forest Laboratories Holdings Limited |
Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
|
|
CN101939004A
(zh)
*
|
2008-01-25 |
2011-01-05 |
阿尔法制药有限公司 |
度洛西汀的缓释药物组合物
|
|
WO2011018801A2
(en)
*
|
2009-08-12 |
2011-02-17 |
Genepharm India Pvt Ltd |
Solid oral dosage form of ziprasidone
|
|
WO2011057176A1
(en)
*
|
2009-11-06 |
2011-05-12 |
Forest Laboratories Holding Limited |
Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
WO2015089494A1
(en)
*
|
2013-12-13 |
2015-06-18 |
Ankenman Ralph |
Compositions and methods for treating dysregulated systems
|
|
CN106061506A
(zh)
*
|
2014-02-07 |
2016-10-26 |
纽罗克里生物科学有限公司 |
包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
|
|
RS61645B1
(sr)
|
2015-10-30 |
2021-04-29 |
Neurocrine Biosciences Inc |
Valbenazin ditozilat i njihovi polimorfi
|
|
JP6869988B2
(ja)
|
2015-12-23 |
2021-05-12 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
（Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
|
|
US10336679B2
(en)
*
|
2016-10-24 |
2019-07-02 |
Syneurx International (Taiwan) Corp. |
Polymorphic forms of sodium benzoate and uses thereof
|
|
CA3051830A1
(en)
|
2017-01-27 |
2018-08-02 |
Neurocrine Bioscienes, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
CA3076000A1
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
MA53239A
(fr)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
|
CN108938645A
(zh)
*
|
2018-08-24 |
2018-12-07 |
山西医科大学第医院 |
一种抗精神病药物组合物
|
|
CN108938635A
(zh)
*
|
2018-08-24 |
2018-12-07 |
山西医科大学第医院 |
一种低剂量非典型抗精神病药物组合物
|
|
CN108926569A
(zh)
*
|
2018-08-24 |
2018-12-04 |
山西医科大学第医院 |
一种非典型抗精神病药物组合物
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CN111084778B
(zh)
*
|
2019-12-31 |
2022-06-24 |
北京鑫开元医药科技有限公司 |
一种奥氮平盐酸氟西汀胶囊及其制备方法
|